• Policy
• Lansoprazole+antacid combo awaits entry into market
• by Lee, Tak-Sun Mar 20, 2023 05:51am

• Policy
• Marketing authorization imminent for Obizur in Korea
• by Lee, Hye-Kyung Mar 17, 2023 05:46am

• Policy
• Upper limit re-evaluation of drugs in the negotiation stage
• by Lee, Tak-Sun Mar 16, 2023 05:45am

• Policy
• MFDS, approval of Vadadustat for anemia tx of renal disease
• by Lee, Hye-Kyung Mar 15, 2023 05:56am

• Policy
• MOHW provides real-time confirmation service
• by Lee, Jeong-Hwan Mar 15, 2023 05:56am

• Policy
• SGLT2 + DPP4 combi benefit expansion has increased
• by Lee, Tak-Sun Mar 14, 2023 05:50am

• Policy
• Voluntary withdrawal of reimbursement for Tepmeko
• by Lee, Tak-Sun Mar 14, 2023 05:50am

• Policy
• Innovative plans for domestic vaccines/txs to face post-pand
• by Lee, Jeong-Hwan Mar 13, 2023 05:53am

• Policy
• Pfizer’s Cibinqo to undergo NHIS negotiations for reimb
• by Lee, Tak-Sun Mar 13, 2023 05:53am

• Policy
• Industry unsatisfied with the proposed PVA improvements
• by Lee, Tak-Sun Mar 10, 2023 05:50am